← All trials
NCT04818320
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 16, 2021
- Primary completion
- Jul 1, 2021
- Completion date
- Jul 13, 2021
- First posted
- Mar 26, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Penang Medical CollegeLead sponsor
- University of AdelaideCollaborator
- Enche' Besar Hajjah Khalsom HospitalCollaborator
- Hulu Terrengganu HospitalCollaborator
- Tuanku Fauziah HospitalCollaborator
- Tuanku Jaafar HospitalCollaborator
- Tumpat HospitalCollaborator
- Jasin HospitalCollaborator
- Kepala Batas HospitalCollaborator
- Tengku Ampuau Afzan Hospital, KuantanCollaborator
- Melaka HospitalCollaborator
- Hospital Sultanah Aminah Johor BahruCollaborator
- Sultanah Nur Zahirah HospitalCollaborator
- Hospital Sungai BulohCollaborator
- Permai HospitalCollaborator
- Raja Perempuan Zainab II HospitalCollaborator
- Hospital Raja Permaisuri BainunCollaborator
- Tampin HospitalCollaborator
- Tawam HospitalCollaborator
- Institute for Clinical ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.